Now live: Pro — the full 13F research suite for serious investorsSee pricing →
CARNEGIE MELLON UNIVERSITY

Q3 2023 · 13F-HR

CARNEGIE MELLON UNIVERSITYholdings as filed

Filed 2023-11-01 · accession 0000898432-23-000741

$78.8M
Reported value
7
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
26603R106DUOLDUOLINGO INC$60.9M77.3%367,314CommonSOLE
46434G103IEMGISHARES INC$17.2M21.8%361,103CommonSOLE
142922103CARMELL THERAPEUTICS CORP$371,3290.47%103,061CommonSOLE
92337R101VERAVERA THERAPEUTICS INC.$220,1830.28%16,060CommonSOLE
64132K102NEUBASE THERAPEUTICS INC.$40,8550.05%46,970CommonSOLE
74039M200PREDICTIVE ONCOLOGY INC.$33,1460.04%10,358CommonSOLE
457919108IHTINNSUITES HOSPITALITY TRUST$12,7000.02%10,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.